Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


iZumi & Pierian Join Forces to Advance EMerging iPS Cell Platform

This article was originally published in Start Up

Executive Summary

Every so often an undeniably important technology emerges resulting in the consolidation of IP and the alignment of thought leaders around a few main players. The new battleground is stem cells. And though the two heavy hitters in the promising induced pluripotent stem (iPS) cell space, Ipierian and Fate Therapeutics, are perhaps less aggressive in publicly asserting their dominance, they've positioned themselves as leading competitors in the still-nascent but rapidly advancing area of cellular reprogramming.

You may also be interested in...

Bristol Shifts Early R&D Focus With iPierian Purchase

The big pharma adds a neurodegenerative asset to its early stage pipeline with the $175 million acquisition of iPierian; the firm will begin with studying the drug in a rare genetic disorder.

Stem-Cell Specialist iPierian Differentiates Its Programs, Spins Out True North Therapeutics

Insider investors committed $30 million to support two separate companies, each aiming to file an IND within 18 months. South San Francisco-based iPierian will concentrate on a candidate with potential in Alzheimer’s disease and related tauopathies, while the newly spun-out True North will focus on a compound targeting the complement system.

Cellular Dynamics Pulls In $40 Million

Cellular Dynamics International, which manufactures human cells for drug assays,has tapped a closely connected syndicate of investors for nearly $41 million in Series B funding, bringing total investment in the firm to $70 million. The fundraising total is impressive for a start-up in a highly speculative area of biotech where VCs have been cautious about committing capital.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts